133 related articles for article (PubMed ID: 27344494)
1. Identification of SENP1 inhibitors through in silico screening and rational drug design.
Zhao Y; Wang Z; Zhang J; Zhou H
Eur J Med Chem; 2016 Oct; 122():178-184. PubMed ID: 27344494
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.
Qiao Z; Wang W; Wang L; Wen D; Zhao Y; Wang Q; Meng Q; Chen G; Wu Y; Zhou H
Bioorg Med Chem Lett; 2011 Nov; 21(21):6389-92. PubMed ID: 21930380
[TBL] [Abstract][Full Text] [Related]
3. Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening.
Kumar A; Ito A; Takemoto M; Yoshida M; Zhang KY
J Chem Inf Model; 2014 Mar; 54(3):870-80. PubMed ID: 24512059
[TBL] [Abstract][Full Text] [Related]
4. Benzothiophene-2-carboxamide derivatives as SENPs inhibitors with selectivity within SENPs family.
Wang Z; Liu Y; Zhang J; Ullah S; Kang N; Zhao Y; Zhou H
Eur J Med Chem; 2020 Oct; 204():112553. PubMed ID: 32717481
[TBL] [Abstract][Full Text] [Related]
5. 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation.
Chen Y; Wen D; Huang Z; Huang M; Luo Y; Liu B; Lu H; Wu Y; Peng Y; Zhang J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6867-70. PubMed ID: 23044371
[TBL] [Abstract][Full Text] [Related]
6. Important role of SUMOylation of Spliceosome factors in prostate cancer cells.
Wen D; Xu Z; Xia L; Liu X; Tu Y; Lei H; Wang W; Wang T; Song L; Ma C; Xu H; Zhu W; Chen G; Wu Y
J Proteome Res; 2014 Aug; 13(8):3571-82. PubMed ID: 25027693
[TBL] [Abstract][Full Text] [Related]
7. Development of small molecule inhibitors and probes of human SUMO deconjugating proteases.
Albrow VE; Ponder EL; Fasci D; Békés M; Deu E; Salvesen GS; Bogyo M
Chem Biol; 2011 Jun; 18(6):722-32. PubMed ID: 21700208
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Class of Potent and Selective Non-competitive Sentrin-Specific Protease 1 Inhibitors.
Lindenmann U; Brand M; Gall F; Frasson D; Hunziker L; Kroslakova I; Sievers M; Riedl R
ChemMedChem; 2020 Apr; 15(8):675-679. PubMed ID: 32083799
[TBL] [Abstract][Full Text] [Related]
9. Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers.
Wei J; Wang H; Zheng Q; Zhang J; Chen Z; Wang J; Ouyang L; Wang Y
Eur J Med Chem; 2022 Nov; 241():114650. PubMed ID: 35939992
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Dual SENP1 and SENP2 Inhibitor.
Brand M; Bommeli EB; Rütimann M; Lindenmann U; Riedl R
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292935
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a new chemotype of noncovalent SENP inhibitors.
Madu IG; Namanja AT; Su Y; Wong S; Li YJ; Chen Y
ACS Chem Biol; 2013 Jul; 8(7):1435-41. PubMed ID: 23614497
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors.
Uno M; Koma Y; Ban HS; Nakamura H
Bioorg Med Chem Lett; 2012 Aug; 22(16):5169-73. PubMed ID: 22801642
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the activity and substrate specificity of the human SENP family of SUMO proteases.
Mendes AV; Grou CP; Azevedo JE; Pinto MP
Biochim Biophys Acta; 2016 Jan; 1863(1):139-47. PubMed ID: 26522917
[TBL] [Abstract][Full Text] [Related]
14. In silico prediction of SARS protease inhibitors by virtual high throughput screening.
Plewczynski D; Hoffmann M; von Grotthuss M; Ginalski K; Rychewski L
Chem Biol Drug Des; 2007 Apr; 69(4):269-79. PubMed ID: 17461975
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the SENP1 mutant C603S-SUMO complex reveals the hydrolytic mechanism of SUMO-specific protease.
Xu Z; Chau SF; Lam KH; Chan HY; Ng TB; Au SW
Biochem J; 2006 Sep; 398(3):345-52. PubMed ID: 16712526
[TBL] [Abstract][Full Text] [Related]
16. Chemical Tools and Biochemical Assays for SUMO Specific Proteases (SENPs).
Jia Y; Claessens LA; Vertegaal ACO; Ovaa H
ACS Chem Biol; 2019 Nov; 14(11):2389-2395. PubMed ID: 31361113
[TBL] [Abstract][Full Text] [Related]
17. In silico fragment-based discovery of DPP-IV S1 pocket binders.
Rummey C; Nordhoff S; Thiemann M; Metz G
Bioorg Med Chem Lett; 2006 Mar; 16(5):1405-9. PubMed ID: 16321524
[TBL] [Abstract][Full Text] [Related]
18. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors.
Xu Y; Li J; Zuo Y; Deng J; Wang LS; Chen GQ
Cancer Lett; 2011 Oct; 309(1):78-84. PubMed ID: 21669491
[TBL] [Abstract][Full Text] [Related]
19. Lead Molecule Prediction and Characterization for Designing MERS-CoV 3C-like Protease Inhibitors: An In silico Approach.
Rahman MM; Hosen MB; Howlader MZH; Kabir Y
Curr Comput Aided Drug Des; 2019; 15(1):82-88. PubMed ID: 29956635
[TBL] [Abstract][Full Text] [Related]
20. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
